查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1360340

同種異體幹細胞市場（類型：未修飾幹細胞移植、T 細胞去除移植、臍帶血移植和供體淋巴細胞輸注[DLI]）- 全球產業分析、規模、佔有率、成長、趨勢和預測，2023-2031年

Allogeneic Stem Cell Market (Type: Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant, and Donor Lymphocyte Infusion [DLI]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 204 Pages | 商品交期: 2-10個工作天內

價格

同種異體幹細胞市場 - 報告範圍

TMR 關於全球同種異體幹細胞市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球同種異體幹細胞的收入2017- 2031年期間的市場，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球同種異體幹細胞市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解同種異體幹細胞市場。

市場概況
2023年市場價值 9.418 億美元
2031 年市場價值 16 億美元
複合年成長率 6.3%

該報告深入探討了全球同種異體幹細胞市場的競爭格局。全球同種異體幹細胞市場的主要參與者已被確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球同種異體幹細胞市場參與者的屬性。

目錄

第一章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 對移植趨勢的見解
  • 技術進步
  • 按地區/全球分類的監管情景
  • COVID-19 大流行對產業的影響（價值鍊和短期/中期/長期影響）

第 6 章：全球市場分析與預測：按類型

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按類型，2017-2031
    • 未經修飾的幹細胞移植
    • T細胞耗盡移植
    • 臍帶血移植
    • 供體淋巴細胞輸注 (DLI)
  • 市場吸引力分析：按類型

第 7 章：全球市場分析與預測：按細胞來源

  • 簡介與定義
  • 主要發現/進展
  • 市值預測：2017-2031年按電池來源
    • 骨髓
    • 週邊血幹細胞（PBSC）
    • 臍帶血
    • 脂肪組織
    • 其他
  • 市場吸引力分析：按細胞來源

第 8 章：全球市場分析與預測：按應用分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依應用分類，2017-2031
    • 肌肉骨骼疾病
    • 心血管疾病
    • 自體免疫疾病
    • 癌症
    • 移植物抗宿主疾病
    • 其他
  • 市場吸引力分析：按應用

第 9 章：全球市場分析與預測：按最終用戶

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2017-2031
    • 醫院
    • 門診手術中心
    • 其他
  • 市場吸引力分析：按最終用戶

第 10 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 按國家/地區分類的市場吸引力

第 11 章：北美市場分析與預測

第 12 章：歐洲市場分析與預測

第 13 章：亞太市場分析與預測

第 14 章：拉丁美洲市場分析與預測

第 15 章：中東和非洲市場分析與預測

第16章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Mesoblast Limited
    • Gamida Cell Ltd.
    • Novartis International AG
    • Cellectis SA
    • Magenta Therapeutics Inc.
    • Fate Therapeutics Inc.
    • Cynata Therapeutics Limited
    • Kiadis Pharma NV
    • Takeda Pharmaceutical Company Limited
    • JCR Pharmaceuticals Co., Ltd.
    • Pluristem Therapeutics Inc.
    • Celularity Inc.
    • Lineage Cell Therapeutics Inc.
    • Nohla Therapeutics Inc.
    • Orchard Therapeutics plc
    • Other Prominent Players
Product Code: TMRGL85776

Allogeneic Stem Cell Market - Scope of Report

TMR's report on the global allogeneic stem cell market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global allogeneic stem cell market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global allogeneic stem cell market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the allogeneic stem cell market.

Market Snapshot
Market Value in 2023US$ 941.8 Mn
Market Value in 2031US$ 1.6 Bn
CAGR6.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global allogeneic stem cell market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global allogeneic stem cell market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global allogeneic stem cell market.

The report delves into the competitive landscape of the global allogeneic stem cell market. Key players operating in the global allogeneic stem cell market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global allogeneic stem cell market profiled in this report.

Key Questions Answered in Global Allogeneic Stem Cell Market Report:

  • What is the sales/revenue generated by allogeneic stem cell across all regions during the forecast period?
  • What are the opportunities in the global allogeneic stem cell market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Allogeneic Stem Cell Market - Research Objectives and Research Approach

The comprehensive report on the global allogeneic stem cell market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global allogeneic stem cell market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global allogeneic stem cell market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Allogeneic Stem Cell Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Allogeneic Stem Cell Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Insights on Trends in Allogeneic Stem Cell Transplantation
  • 5.2. Technological Advancements
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Allogeneic Stem Cell Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. Unmodified Stem Cell Transplant
    • 6.3.2. T-cell Depleted Transplant
    • 6.3.3. Cord Blood Transplant
    • 6.3.4. Donor Lymphocyte Infusion (DLI)
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Allogeneic Stem Cell Market Analysis and Forecast, by Cell Source

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Cell Source, 2017-2031
    • 7.3.1. Bone Marrow
    • 7.3.2. Peripheral Blood Stem Cell (PBSC)
    • 7.3.3. Umbilical Cord Blood
    • 7.3.4. Adipose Tissue
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Cell Source

8. Global Allogeneic Stem Cell Market Analysis and Forecast, by Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Application, 2017-2031
    • 8.3.1. Musculoskeletal Disease
    • 8.3.2. Cardiovascular Disease
    • 8.3.3. Autoimmune Disease
    • 8.3.4. Cancer
    • 8.3.5. GvHD
    • 8.3.6. Others
  • 8.4. Market Attractiveness Analysis, by Application

9. Global Allogeneic Stem Cell Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Hospital
    • 9.3.2. Ambulatory Surgical Center
    • 9.3.3. Others
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Allogeneic Stem Cell Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Country/Region

11. North America Allogeneic Stem Cell Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type, 2017-2031
    • 11.2.1. Unmodified Stem Cell Transplant
    • 11.2.2. T-cell Depleted Transplant
    • 11.2.3. Cord Blood Transplant
    • 11.2.4. Donor Lymphocyte Infusion (DLI)
  • 11.3. Market Value Forecast, by Cell Source, 2017-2031
    • 11.3.1. Bone Marrow
    • 11.3.2. Peripheral Blood Stem Cell (PBSC)
    • 11.3.3. Umbilical Cord Blood
    • 11.3.4. Adipose Tissue
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Application, 2017-2031
    • 11.4.1. Musculoskeletal Disease
    • 11.4.2. Cardiovascular Disease
    • 11.4.3. Autoimmune Disease
    • 11.4.4. Cancer
    • 11.4.5. GvHD
    • 11.4.6. Others
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Hospital
    • 11.5.2. Ambulatory Surgical Center
    • 11.5.3. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Cell Source
    • 11.7.3. By Application
    • 11.7.4. By End-user
    • 11.7.5. By Country/Sub-region

12. Europe Allogeneic Stem Cell Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type, 2017-2031
    • 12.2.1. Unmodified Stem Cell Transplant
    • 12.2.2. T-cell Depleted Transplant
    • 12.2.3. Cord Blood Transplant
    • 12.2.4. Donor Lymphocyte Infusion (DLI)
  • 12.3. Market Value Forecast, by Cell Source, 2017-2031
    • 12.3.1. Bone Marrow
    • 12.3.2. Peripheral Blood Stem Cell (PBSC)
    • 12.3.3. Umbilical Cord Blood
    • 12.3.4. Adipose Tissue
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Application, 2017-2031
    • 12.4.1. Musculoskeletal Disease
    • 12.4.2. Cardiovascular Disease
    • 12.4.3. Autoimmune Disease
    • 12.4.4. Cancer
    • 12.4.5. GvHD
    • 12.4.6. Others
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Hospital
    • 12.5.2. Ambulatory Surgical Center
    • 12.5.3. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Cell Source
    • 12.7.3. By Application
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Allogeneic Stem Cell Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type, 2017-2031
    • 13.2.1. Unmodified Stem Cell Transplant
    • 13.2.2. T-cell Depleted Transplant
    • 13.2.3. Cord Blood Transplant
    • 13.2.4. Donor Lymphocyte Infusion (DLI)
  • 13.3. Market Value Forecast, by Cell Source, 2017-2031
    • 13.3.1. Bone Marrow
    • 13.3.2. Peripheral Blood Stem Cell (PBSC)
    • 13.3.3. Umbilical Cord Blood
    • 13.3.4. Adipose Tissue
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Application, 2017-2031
    • 13.4.1. Musculoskeletal Disease
    • 13.4.2. Cardiovascular Disease
    • 13.4.3. Autoimmune Disease
    • 13.4.4. Cancer
    • 13.4.5. GvHD
    • 13.4.6. Others
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Hospital
    • 13.5.2. Ambulatory Surgical Center
    • 13.5.3. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Cell Source
    • 13.7.3. By Application
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Allogeneic Stem Cell Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type, 2017-2031
    • 14.2.1. Unmodified Stem Cell Transplant
    • 14.2.2. T-cell Depleted Transplant
    • 14.2.3. Cord Blood Transplant
    • 14.2.4. Donor Lymphocyte Infusion (DLI)
  • 14.3. Market Value Forecast, by Cell Source, 2017-2031
    • 14.3.1. Bone Marrow
    • 14.3.2. Peripheral Blood Stem Cell (PBSC)
    • 14.3.3. Umbilical Cord Blood
    • 14.3.4. Adipose Tissue
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Application, 2017-2031
    • 14.4.1. Musculoskeletal Disease
    • 14.4.2. Cardiovascular Disease
    • 14.4.3. Autoimmune Disease
    • 14.4.4. Cancer
    • 14.4.5. GvHD
    • 14.4.6. Others
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Hospital
    • 14.5.2. Ambulatory Surgical Center
    • 14.5.3. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Cell Source
    • 14.7.3. By Application
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Allogeneic Stem Cell Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Type, 2017-2031
    • 15.2.1. Unmodified Stem Cell Transplant
    • 15.2.2. T-cell Depleted Transplant
    • 15.2.3. Cord Blood Transplant
    • 15.2.4. Donor Lymphocyte Infusion (DLI)
  • 15.3. Market Value Forecast, by Cell Source, 2017-2031
    • 15.3.1. Bone Marrow
    • 15.3.2. Peripheral Blood Stem Cell (PBSC)
    • 15.3.3. Umbilical Cord Blood
    • 15.3.4. Adipose Tissue
    • 15.3.5. Others
  • 15.4. Market Value Forecast, by Application, 2017-2031
    • 15.4.1. Musculoskeletal Disease
    • 15.4.2. Cardiovascular Disease
    • 15.4.3. Autoimmune Disease
    • 15.4.4. Cancer
    • 15.4.5. GvHD
    • 15.4.6. Others
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Hospital
    • 15.5.2. Ambulatory Surgical Center
    • 15.5.3. Others
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Type
    • 15.7.2. By Cell Source
    • 15.7.3. By Application
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Mesoblast Limited
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Gamida Cell Ltd.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Novartis International AG
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Cellectis SA
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Magenta Therapeutics Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Fate Therapeutics Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Cynata Therapeutics Limited
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Kiadis Pharma N.V.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Takeda Pharmaceutical Company Limited
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. JCR Pharmaceuticals Co., Ltd.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Pluristem Therapeutics Inc.
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Celularity Inc.
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview
    • 16.3.13. Lineage Cell Therapeutics Inc.
      • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.13.2. Product Portfolio
      • 16.3.13.3. Financial Overview
      • 16.3.13.4. SWOT Analysis
      • 16.3.13.5. Strategic Overview
    • 16.3.14. Nohla Therapeutics Inc.
      • 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.14.2. Product Portfolio
      • 16.3.14.3. Financial Overview
      • 16.3.14.4. SWOT Analysis
      • 16.3.14.5. Strategic Overview
    • 16.3.15. Orchard Therapeutics plc
      • 16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.15.2. Product Portfolio
      • 16.3.15.3. Financial Overview
      • 16.3.15.4. SWOT Analysis
      • 16.3.15.5. Strategic Overview
    • 16.3.16. Other Prominent Players
      • 16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.16.2. Product Portfolio
      • 16.3.16.3. Financial Overview
      • 16.3.16.4. SWOT Analysis
      • 16.3.16.5. Strategic Overview

List of Tables

  • Table 01: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 02: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 03: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 04: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 08: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 09: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 10: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 11: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 13: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 14: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 15: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 16: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 18: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 19: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 20: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 23: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 24: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 25: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 28: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 29: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 30: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Allogeneic Stem Cell Market Value Share, by Type, 2022
  • Figure 03: Allogeneic Stem Cell Market Value Share, by Cell Source, 2022
  • Figure 04: Allogeneic Stem Cell Market Value Share, by Application, 2022
  • Figure 05: Allogeneic Stem Cell Market Value Share, by End-user, 2022
  • Figure 06: Global Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 07: Global Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 08: Global Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 09: Global Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
  • Figure 10: Global Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 11: Global Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
  • Figure 12: Global Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 13: Global Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 14: Global Allogeneic Stem Cell Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 15: Global Allogeneic Stem Cell Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 16: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 17: North America Allogeneic Stem Cell Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 18: North America Allogeneic Stem Cell Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 19: North America Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 20: North America Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 21: North America Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 22: North America Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
  • Figure 23: North America Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 24: North America Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
  • Figure 25: North America Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 26: North America Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 27: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: Europe Allogeneic Stem Cell Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 29: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 30: Europe Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 31: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 32: Europe Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 33: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
  • Figure 34: Europe Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 35: Europe Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
  • Figure 36: Europe Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 37: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 38: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 39: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 40: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 41: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 42: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 43: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 44: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
  • Figure 45: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 46: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
  • Figure 47: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 48: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 49: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 51: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 52: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 53: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 54: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 55: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source, 2023-2031
  • Figure 56: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 57: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
  • Figure 58: Latin America Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 59: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 60: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 62: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 63: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 64: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 65: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 66: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
  • Figure 67: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 68: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 69: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 70: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 71: Global Allogeneic Stem Cell Market Share Analysis By Company (2022)